Nilai Dipunlarasaken Utang lan Kas: Vaxart (VXRT)

Vaxart, Inc. (VXRT) is developing innovative tablet vaccines based on VAAST, replacing injections with convenient capsule administration for protection against norovirus and influenza. However, the narrow development focus carries significant binary risks. This chart reflects an asset value of . The elimination of cold-chain requirements during transport substantially reduces distribution costs and ensures stable medication supplies.

Enterprise value is calculated as the sum of market capitalization and net debt, determining the total cost of a full business buyout accounting for liquid reserves. For Vaxart, Inc. (VXRT) and its capital-intensive R&D pipeline of oral vaccines, this metric reflects the financial burden of scaling the VAAST platform, allowing for an assessment of investment attractiveness through the enterprise value structure.